Lilly’s Basal Insulin Peglispro Shows Superiority in HbA1c Reduction Compared to Insulin Glargine in Three Phase III Trials in Patients with Type 2 Diabetes

[PR Newswire] – INDIANAPOLIS, May 12, 2014 /PRNewswire/ — Eli Lilly and Company (LLY) today announced positive top-line results of three completed Phase III clinical trials in patients with type 2 diabetes for basal insulin peglispro (BIL), which is bei more

View todays social media effects on LLY

View the latest stocks trending across Twitter. Click to view dashboard

See who Eli is hiring next, click here to view